article thumbnail

In Brain Chemistry We Trust—The Gospel According to Pharma

Mad in America

Depression was sold to us as a simple problem of serotonin insufficiency, a convenient narrative that made drug companies like Eli Lilly, Forest Pharmaceuticals, and Pfizer very rich. As a former pharmaceutical advertising writer, I not only witnessed the explosive growth in antidepressant drugs, I contributed to it.

article thumbnail

Heritability Explains Less About Mental Disorders Than You Think

Mad in America

In a corresponding study led by Jim van Os , a long-standing schizophrenia expert at the University of Utrecht in the Netherlands, differences in genes only explained 3 percent of the symptoms. Regarding mental disorders, pharmaceutical treatments appear better if genetic causes are assumed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Two Decades of PSSD: A Life Stolen by Antidepressants

Mad in America

Once again, a pharmaceutical had altered an essential part of my body. Countless supplements and over 30 different pharmaceuticals, I pretty much tried it all. The medical field has become complacent, prioritizing pharmaceutical profits, insurance companies agendas, and established narratives over patients well-being.

article thumbnail

Criticisms That Establishment Psychiatry Can and Cannot Tolerate

Mad in America

Corruption by pharmaceutical companies. Whitaker makes clear that correlation is not equivalent to causation, and that increasing mental illness disability rates corresponding with increased psychiatric drug treatment is not proof of his hypothesis, but rather should provoke scientific inquiry.

article thumbnail

Grossly Flawed Paper Denies that Antidepressant Withdrawal Effects are “Clinically Meaningful”

Mad in America

Global pharmaceutical revenue is about $1.6 The minimising begins in the title, where they use the term Discontinuation Symptoms, invented by the pharmaceutical industry to create the impression that the phenomenon in question is somehow different from, and lesser than, withdrawal effects. about $80 billion).

article thumbnail

Treat Systems, Not Symptoms: Defending the Sanity of the Oppressed

Mad in America

through profitable institutions like psychiatry, hospitals, pharmaceutical companies) and as an added benefit dampens the psychological responses that could subvert oppressive systems (e.g., Southeast Asia, Africa, and the Caribbean), increasing pollution, and a corresponding growing burden of disease in affected communities.

article thumbnail

Cochrane Recommends Antidepressants for Anxiety in a Garbage In, Garbage Out Review

Mad in America

The Cochrane abstract noted that the tiny effect they found corresponds to a number needed to treat (NNT) of seven to benefit one patient. corresponds to 2 on the Hamilton scale). Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.